FactorH抗体;FactorH Antibody—艾普蒂 新品

+ +

•  

   

     Western blot analysis of Factor H expression in human plasma lysate.    

  
  

Factor H (FH) antibodies are immunological tools designed to target complement factor H, a critical regulatory protein in the complement system. Factor H, a 155 kDa glycoprotein produced primarily in the liver, plays a pivotal role in inhibiting the alternative complement pathway. It prevents uncontrolled activation by binding to host cell surfaces and microbial pathogens, blocking C3 convertase formation, and accelerating its decay. Dysregulation of FH is linked to several diseases, including atypical hemolytic uremic syndrome (aHUS), age-related macular degeneration (AMD), and C3 glomerulopathy.

FH antibodies, both polyclonal and monoclonal, are widely used in research and diagnostics. They enable the detection and quantification of FH in biological samples via techniques like ELISA, Western blotting, and immunohistochemistry. In therapeutic contexts, anti-FH antibodies are explored to modulate complement activity. For example, neutralizing antibodies may counteract pathogenic FH variants in aHUS, while enhancing antibodies could stabilize FH function in AMD. However, challenges persist, such as ensuring target specificity and avoiding unintended complement activation.

Therapeutic development has seen mixed outcomes; lampalizumab, an anti-FH Fab antibody tested for AMD, showed limited efficacy in clinical trials. Nonetheless, FH antibodies remain vital for studying complement-related pathologies and advancing precision therapies targeting the complement cascade.